Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket studyMore about Open Access at the Crick
Authors listFunda Meric-Bernstam Herbert Hurwitz Kanwal Pratap Singh Raghav Robert R McWilliams Marwan Fakih Ari VanderWalde Charles Swanton Razelle Kurzrock Howard Burris Christopher Sweeney Ron Bose David R Spigel Mary S Beattie Steven Blotner Alyssa Stone Katja Schulze Vaikunth Cuchelkar John Hainsworth
Therapies targeting HER2 have improved clinical outcomes in HER2-positive breast and gastric cancers, and are emerging as potential treatments for HER2-positive metastatic colorectal cancer. MyPathway evaluates the activity of targeted therapies in non-indicated tumour types with potentially predictive molecular alterations. We aimed to assess the activity of pertuzumab and trastuzumab in patients with HER2-amplified metastatic colorectal cancer.
Journal Lancet Oncology
Issue number 4
Full text links
Publisher website (DOI) 10.1016/s1470-2045(18)30904-5
Europe PubMed Central 30857956